| Original language | English (US) |
|---|---|
| Pages (from-to) | 433-435.e3 |
| Journal | Journal of Allergy and Clinical Immunology: In Practice |
| Volume | 3 |
| Issue number | 3 |
| DOIs | |
| State | Published - 2015 |
ASJC Scopus subject areas
- Immunology and Allergy
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Modified peanut oral immunotherapy protocol safely and effectively induces desensitization. / Bird, J. Andrew; Feldman, Matthew; Arneson, Amy et al.
In: Journal of Allergy and Clinical Immunology: In Practice, Vol. 3, No. 3, 2015, p. 433-435.e3.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Modified peanut oral immunotherapy protocol safely and effectively induces desensitization
AU - Bird, J. Andrew
AU - Feldman, Matthew
AU - Arneson, Amy
AU - Dougherty, Irene
AU - Brown, L. Steven
AU - Burk, Caitlin M.
AU - Kulis, Michael
AU - Burks, Wesley
AU - Gill, Michelle
N1 - Funding Information: The study was funded by Dedman Family Scholar in Clinical Care funds at UT Southwestern Medical Center, Dallas, Tex. Funding Information: Conflicts of interest: J. A. Bird has received research support from the Dedman Family in Clinical Care Funding and Food Allergy Research and Education ; has received consultancy fees from SRA International; has received lecture fees from Nutricia; has participated in epicutaneous patch immunotherapy for peanut multicentered trial for DBV Technologies; and has participated in peanut oral immunotherapy multicentered trial for Allergen Research Corporation. M. Feldman has received consultancy fees from Patient Point, and is employed by the Dallas Allergy & Asthma Center. L. S. Brown has received fees from UT Southwestern for statistical analysis, and is employed by Parkland Hospital. M. Kulis is employed by the University of North Carolina at Chapel Hill, and has received research support from the National Institutes of Health (NIH). A. W. Burks was on the Merck Board; has received consultancy fees from Dow AgroSciences, Exploramed Development, GLG Research, McNeill Nutritionals, Merck, Novartis Pharma, Regeneron Pharmaceuticals, Unilever, ActoGeniX, SRA International, Genentech, Sanofi US Services, and Nutricia North America; is employed by the University of North Carolina; has received research support from the NIH, Hycor Biomedical, and Allergen Research Corporation; has received lecture fees from Mylan Specialty; and has stock/stock options in Allertein and Mastcell Pharmaceuticals. M. Gill has received research and travel support from the NIH/National Institute of Allergy and Infectious Diseases. The rest of the authors declare that they have no relevant conflicts. Copyright: Copyright 2018 Elsevier B.V., All rights reserved.
PY - 2015
Y1 - 2015
UR - http://www.scopus.com/inward/record.url?scp=84939783262&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84939783262&partnerID=8YFLogxK
U2 - 10.1016/j.jaip.2014.11.020
DO - 10.1016/j.jaip.2014.11.020
M3 - Article
C2 - 25609341
AN - SCOPUS:84939783262
SN - 2213-2198
VL - 3
SP - 433-435.e3
JO - Journal of Allergy and Clinical Immunology: In Practice
JF - Journal of Allergy and Clinical Immunology: In Practice
IS - 3
ER -